4-MeO-MiPT Stats & Data

Harm-reduction clarifications and updates:

• Avoid nickname confusion: “Moxy” commonly refers to 5‑MeO‑MiPT, not 4‑MeO‑MiPT; mislabeling has led to hazardous outcomes in the past. Verify substance identity before dosing.

• Allergy test every new batch: With rare RCs, start with ~1 mg oral allergy test at least 24 h before any active dose; this is a longstanding HR practice echoed by Erowid.

• Reagent testing helps only as a first-pass screen: Indole tryptamines react positive with Ehrlich; many tryptamines (incl. 5‑MeO‑MiPT) give yellow→black with Marquis. Reagents cannot confirm 4‑MeO‑MiPT identity; send to a lab if possible.

• Measurement matters: Use a 0.001 g scale or volumetric dosing for precise titration of small doses. Avoid eyeballing powders. TripSit provides a volumetric converter tool.

• Duration tends to be short/moderate with a tactile, sociable headspace; several users find 20–30 mg oral to produce mild-to-moderate effects with limited visuals. Stronger effects are possible near the top of the range; titrate cautiously.

• Combining 4‑oxygenated tryptamines with 5‑MeO tryptamines can yield unexpectedly strong effects; if combining at all, lower both doses and have a sitter.

• Polydrug risks: The general combo literature flags MAOIs, tramadol, DXM, and serotonergic antidepressants as higher‑risk pairings due to serotonin toxicity or seizure risk; treat these as contraindicated unless medically supervised.

• Because samples are rare and data sparse, expect variability across batches and treat all data as provisional; prefer single‑substance trials and avoid stacking on first exposures.